Goldman Sachs
AKRO

Goldman Sachs’s Akero Therapeutics AKRO Stock Holding History

Goldman Sachs’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,000
Closed -$258K – 6045
2020
Q4 		$258K Hold
10,000
– – ﹤0.01% 4958
2020
Q3 		$308K Buy
+10,000
New +$349K ﹤0.01% 4727

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Goldman Sachs's AKRO Position: Q4 2025 in Review

Goldman Sachs sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 855,766 shares — an estimated $40.6M sold.

Goldman Sachs first reported a position in AKRO in Q2 2019 and held it in 26 quarters. The position peaked at $72.1M in Q3 2022. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Goldman Sachs reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Goldman Sachs sold 855,766 Akero Therapeutics shares in Q4 2025, an estimated $40.6M.
  • Goldman Sachs first reported a position in Akero Therapeutics in Q2 2019 and held it in 26 quarters.
  • Goldman Sachs's Akero Therapeutics position peaked at $72.1M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Goldman Sachs's 13F filing for Q4 2025, filed 10 Feb 2026.